383 related articles for article (PubMed ID: 8857999)
1. Malignant astrocytomas with homozygous CDKN2/p16 gene deletions have higher Ki-67 proliferation indices.
Ono Y; Tamiya T; Ichikawa T; Kunishio K; Matsumoto K; Furuta T; Ohmoto T; Ueki K; Louis DN
J Neuropathol Exp Neurol; 1996 Oct; 55(10):1026-31. PubMed ID: 8857999
[TBL] [Abstract][Full Text] [Related]
2. CDKN2/p16 or RB alterations occur in the majority of glioblastomas and are inversely correlated.
Ueki K; Ono Y; Henson JW; Efird JT; von Deimling A; Louis DN
Cancer Res; 1996 Jan; 56(1):150-3. PubMed ID: 8548755
[TBL] [Abstract][Full Text] [Related]
3. Alterations of retinoblastoma, p53, p16(CDKN2), and p15 genes in human astrocytomas.
Tsuzuki T; Tsunoda S; Sakaki T; Konishi N; Hiasa Y; Nakamura M
Cancer; 1996 Jul; 78(2):287-93. PubMed ID: 8674005
[TBL] [Abstract][Full Text] [Related]
4. Alterations of the cyclin D1/p16-pRB pathway in mantle cell lymphoma.
Dreyling MH; Bullinger L; Ott G; Stilgenbauer S; Müller-Hermelink HK; Bentz M; Hiddemann W; Döhner H
Cancer Res; 1997 Oct; 57(20):4608-14. PubMed ID: 9377576
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic and prognostic significance of cyclin A expression in low-grade astrocytomas: comparison with astrogliosis and high-grade tumours.
Hara A; Saegusa M; Ichinoe M; Okayasu I
J Clin Pathol; 2008 Mar; 61(3):287-92. PubMed ID: 18156430
[TBL] [Abstract][Full Text] [Related]
6. Loss of P16INK4 expression is frequent in high grade gliomas.
Nishikawa R; Furnari FB; Lin H; Arap W; Berger MS; Cavenee WK; Su Huang HJ
Cancer Res; 1995 May; 55(9):1941-5. PubMed ID: 7728764
[TBL] [Abstract][Full Text] [Related]
7. Deletion and mutation analyses of the P16/MTS-1 tumor suppressor gene in human ductal pancreatic cancer reveals a higher frequency of abnormalities in tumor-derived cell lines than in primary ductal adenocarcinomas.
Huang L; Goodrow TL; Zhang SY; Klein-Szanto AJ; Chang H; Ruggeri BA
Cancer Res; 1996 Mar; 56(5):1137-41. PubMed ID: 8640773
[TBL] [Abstract][Full Text] [Related]
8. Abnormalities of p16, p15 and CDK4 genes in recurrent malignant astrocytomas.
Saxena A; Robertson JT; Ali IU
Oncogene; 1996 Aug; 13(3):661-4. PubMed ID: 8760309
[TBL] [Abstract][Full Text] [Related]
9. CDKN2/p16 inactivation and p16 immunohistochemistry in astrocytic gliomas.
Piva R; Cavalla P; Bortolotto S; Cordera S; Grosso R; Richiardi P; Dutto A; Schiffer D
Int J Oncol; 1998 Jan; 12(1):55-8. PubMed ID: 9454886
[TBL] [Abstract][Full Text] [Related]
10. Homozygous deletions of the multiple tumor suppressor gene 1 in the progression of human astrocytomas.
Walker DG; Duan W; Popovic EA; Kaye AH; Tomlinson FH; Lavin M
Cancer Res; 1995 Jan; 55(1):20-3. PubMed ID: 7805033
[TBL] [Abstract][Full Text] [Related]
11. CDKN2A gene deletions and loss of p16 expression occur in osteosarcomas that lack RB alterations.
Nielsen GP; Burns KL; Rosenberg AE; Louis DN
Am J Pathol; 1998 Jul; 153(1):159-63. PubMed ID: 9665476
[TBL] [Abstract][Full Text] [Related]
12. Frequent homozygous deletion of cyclin-dependent kinase inhibitor 2 (MTS1, p16) in superficial bladder cancer detected by fluorescence in situ hybridization.
Balázs M; Carroll P; Kerschmann R; Sauter G; Waldman FM
Genes Chromosomes Cancer; 1997 Jun; 19(2):84-9. PubMed ID: 9171998
[TBL] [Abstract][Full Text] [Related]
13. Molecular analysis of P16(Ink4)/CDKN2 and P15(INK4B)/MTS2 genes in primary human testicular germ cell tumors.
Heidenreich A; Gaddipati JP; Moul JW; Srivastava S
J Urol; 1998 May; 159(5):1725-30. PubMed ID: 9554401
[TBL] [Abstract][Full Text] [Related]
14. High frequency of p53 protein accumulation without p53 gene mutation in human juvenile pilocytic, low grade and anaplastic astrocytomas.
Lang FF; Miller DC; Pisharody S; Koslow M; Newcomb EW
Oncogene; 1994 Mar; 9(3):949-54. PubMed ID: 8108140
[TBL] [Abstract][Full Text] [Related]
15. MTS1/p16/CDKN2 lesions in primary glioblastoma multiforme.
Moulton T; Samara G; Chung WY; Yuan L; Desai R; Sisti M; Bruce J; Tycko B
Am J Pathol; 1995 Mar; 146(3):613-9. PubMed ID: 7887443
[TBL] [Abstract][Full Text] [Related]
16. Loss of expression of the p16/cyclin-dependent kinase inhibitor 2 tumor suppressor gene in melanocytic lesions correlates with invasive stage of tumor progression.
Reed JA; Loganzo F; Shea CR; Walker GJ; Flores JF; Glendening JM; Bogdany JK; Shiel MJ; Haluska FG; Fountain JW
Cancer Res; 1995 Jul; 55(13):2713-8. PubMed ID: 7796391
[TBL] [Abstract][Full Text] [Related]
17. CDKN2/p16 predicts survival in oligodendrogliomas: comparison with astrocytomas.
Miettinen H; Kononen J; Sallinen P; Alho H; Helen P; Helin H; Kalimo H; Paljärvi L; Isola J; Haapasalo H
J Neurooncol; 1999 Feb; 41(3):205-11. PubMed ID: 10359140
[TBL] [Abstract][Full Text] [Related]
18. Hypermethylation of the CpG island of p16/CDKN2 correlates with gene inactivation in gliomas.
Fueyo J; Gomez-Manzano C; Bruner JM; Saito Y; Zhang B; Zhang W; Levin VA; Yung WK; Kyritsis AP
Oncogene; 1996 Oct; 13(8):1615-9. PubMed ID: 8895506
[TBL] [Abstract][Full Text] [Related]
19. Homozygous deletions of cyclin-dependent kinase inhibitor genes, p16(INK4A) and p18, in childhood T cell lineage acute lymphoblastic leukemias.
Iolascon A; Faienza MF; Coppola B; della Ragione F; Schettini F; Biondi A
Leukemia; 1996 Feb; 10(2):255-60. PubMed ID: 8637234
[TBL] [Abstract][Full Text] [Related]
20. [Loss of CDKN2 gene and amplification of cyclin D1 gene in human esophageal cancer].
Zheng J; Hou P; Zhou C
Zhonghua Zhong Liu Za Zhi; 1996 Nov; 18(6):408-11. PubMed ID: 9387288
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
